Clinical trials: Herpes Simplex Infections
Shingles
Optimal Timing of Zoster Vaccine After Zoster Illness
The purpose of this study is to determine the optimal timing of zoster vaccination to induce both higher cell-mediated immunity and humoral immunity in adult patients aged over 50 with history of zoster within 5 years.
- Trial name
- NCT02704572
- Testing
- Zostavax
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Herpes Simplex
Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine
Evaluate, one month after the third dose, the lot-to-lot consistency of 3 different commercial scale production lots of the candidate vaccine in healthy HSV 1-/2- females aged 10-17 years, determined by ELISA.
- Trial name
- NCT00224471
- Testing
- GSK208141 vaccine
- Where
- 13 sites in United States, Belgium and 1 more
- Volunteers
- 671 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chickenpox, Herpes Zoster
Immune Response to Varicella-Zoster Vaccination and Infection
Background: The common varicella-zoster virus causes both chickenpox and shingles. Both diseases cause rashes, but they can also have complications such as bacterial infections of the skin, pneumonia, or eye disease.
- Trial name
- NCT00921999
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Herpes Zoster
Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell).
To evaluate the lot-to lot consistency of three batches of recombinant herpes zoster vaccine (CHO cell) produced on a commercial scale in subjects aged 40 years and older after receiving 2 doses on a 0, 2 month schedule.
- Trial name
- NCT06654700
- Testing
- Recombinant Zoster Vaccine (CHO Cell)
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- MAXVAX Biotechnology Limited Liability Company
Herpes Zoster
Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects
The subjects included in this study are subjects that participated in study NCT00434577. These subjects were vaccinated with the candidate Herpes Zoster (HZ) vaccine at Month 0 and Month 2 and were then followed at Month 12…
- Trial name
- NCT01295320
- Testing
- Blood sample
- Where
- 11 sites in Czechia, Germany and 2 more
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes
Bioequivalency Study of Famciclovir 500 mg Tablets Under Fasted Conditions
The objective of this study was to prove the bioequivalence of Famciclovir 500 mg Tablets under fasting conditions.
- Trial name
- NCT01321515
- Testing
- famciclovir
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories